Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

s or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The studies will enroll approximately 375 patients each at more than 160 sites in North America, South America, Europe, Australia and South Africa.

"As a next-generation HIV entry inhibitor, vicriviroc has the potential to benefit a broad range of patients by offering a potent, sustained viral response and a single once-daily dose in combination with optimized background therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "There is an urgent need for new antiretroviral agents with novel mechanisms of action and we look forward to the further clinical evaluation of vicriviroc in these large global studies."

About the VICTOR-E3 and VICTOR-E4 Phase III Studies

VICTOR-E3 and VICTOR-E4 are identically designed, randomized, double- blind, placebo-controlled, parallel group, multicenter studies of vicriviroc in adult treatment-experienced patients infected with CCR5-tropic HIV virus (no detectable CXCR4-tropic or dual/mixed CCR5/CXCR4-tropic virus at screening).

The primary efficacy endpoint of the studies will be the proportion of patients with plasma HIV-1 RNA less than 50 copies/mL at week 48. Key secondary endpoints, each measured at 48 weeks, include the proportion of patients with less than 400 copies/mL of plasma HIV-1 RNA, mean change from baseline in plasma HIV-1 RNA (log10 copies/mL) and mean change from baseline CD4+ count. All efficacy endpoints will also be evaluated at week 24.

Patients in VICTOR-E3 and VICTOR-E4 must have documented resistance to at least two of the three antiretroviral drug classes (NRTI, NNRTI or PI)(2-4) or 6 months or more of experience with at least two of the following: one NRTI, one NNRTI or two PIs (excluding low-dose ritonavir); and must have plasma HIV- 1 RNA levels above 1000 copies/mL. The optimized background therapy must include a prote
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
(Date:7/31/2014)... July 31, 2014 The Galien Foundation today ... Galien USA Awards. The Prix ... and recognizes the technical, scientific and clinical research skills ... This year brings the highest number of nominees since ... . Nominees include biomedical products across three categories ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... ... ... EST Q It,s an interesting time, so we really are eager to talk to you about,especially ... I,d love your overall assessment from -- of what,s,been happening on the Hill, like Pelosi,s leadership and ...
... Data from 11 PROCRIT(R) (Epoetin alfa),studies will be presented at the ... - 11, 2007., The data will provide ... blood supply of limiting the use of ... chemotherapy-induced anemia (CIA); -- the use of PROCRIT in extended ...
Cached Medicine Technology:Interview of the Vice President 2Interview of the Vice President 3Interview of the Vice President 4Interview of the Vice President 5Interview of the Vice President 6Interview of the Vice President 7Interview of the Vice President 8Interview of the Vice President 9Interview of the Vice President 10Interview of the Vice President 11Interview of the Vice President 12Interview of the Vice President 13Interview of the Vice President 14Interview of the Vice President 15Interview of the Vice President 16PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 2PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 4PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 5PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 6PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 7PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 8PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 9
(Date:7/31/2014)... 2014 Cosmetic Town is a new ... to consumers considering cosmetic treatments. The site features ... goal is to educate prospective patients on a variety ... a validated referral system that helps patients find cosmetic ... their respective fields. , Cosmetic Town started its ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Current residents ... abuse treatment program in Flagstaff, AZ, learn to kayak ... of equipment and paddle strokes in preparation for next ... , "I think that [the kayaking course] teaches [residents] ... they struggle with in their early part of their ...
(Date:7/31/2014)... CarePoint Health is proud to ... has joined our network, CarePoint Health Medical Group. ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ... represents CarePoint Health’s commitment to provide the highest ...
(Date:7/31/2014)... 31, 2014 DocbookMD , a ... Haas and Tim Gueramy, announced the on-boarding of six ... According to Dr. Tim Gueramy, CEO of DocbookMD, most ... physician leaders from each one had been using the ... benefit for their respective organizations to adopt the HIPAA-secure ...
Breaking Medicine News(10 mins):Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Physician Demand for Integrated Communication Platform Drives DocbookMD Growth 2
... FAIRFIELD, Calif., Dec. 3 With Sutter Regional ... Medical,Campus, community residents now have access to a ... location., The three-story, 69,000-square-foot care center, located ... location, providing an enhanced,environment and room for growth. ...
... be to blame, researchers say , MONDAY, Dec. 3 (HealthDay ... than other males to develop the eating disorder anorexia nervosa, ... to female sex hormones in the womb may be associated ... researchers. , "Anorexia nervosa is approximately 10 times more common ...
... Australia has identified an upper limit for ALT that is ... could facilitate targeted interventions for the youths in this group, ... liver disease. The study is in the December issue of ... behalf of the American Association for the Study of Liver ...
... Seniors who take a close look at,the Part ... reap,handsome savings next year. Many Medicare HMO and PPO ... deductibles with either complete or,partial coverage throughout the "gap" ... bills until reaching $4,050 in out-of-pocket costs).,HealthMetrix Research Inc. ...
... Patrick O,Connell, former Chief,of the Texas Attorney ... & Budd, P.C., as Special Counsel in the ... the firm,s Qui Tam litigation team, representing,government entities ... public through corporate fraud., O,Connell served in ...
... Diagnostic Imaging Management Services for SWHP, DEERFIELD, ... operating subsidiary of WellPoint, Inc. (NYSE: WLP ... company with health,plan clients representing over 20 million ... provide a radiology quality program around,diagnostic imaging services ...
Cached Medicine News:Health News:Sutter Regional Medical Foundation Opens New Fairfield Care Center 2Health News:Having Twin Sister Boosts Men's Anorexia Risk 2Health News:New upper limit defined for normal ALT in adolescent males 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 3Health News:Former Texas Assistant Attorney General Pat O'Connell Joins Baron & Budd, P.C., to Lead Whistleblower Litigation Practice 2Health News:American Imaging Management Enters into Agreement with Scott & White Health Plan 2
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: